

- 22 Rimm DL, Sinard JH, Morrow JS: Reduced α -catenin and E-cadherin expression in breast cancer. *Lab Invest* 1995;72:506–512.
- 23 Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. *Proc Natl Acad Sci USA* 1990;87:8751–8755.
- 24 Mansouri A, Spurr N, Goodfellow PN, Kemler R: Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin. *Differentiation* 1988;38:67–71.
- 25 Ruijter E, van de Kaa C, Adadars T, Ruiter D, Miller G, Debruyne F, members of the BIOMED-II markers for prostate cancer study group, Schalken J: Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. *Mod Pathol* 1998;11:276–281.
- 26 Loric S, Paradis V, Gala JL, Berteau P, Bedossa P, Benoit G, Eschwege P: Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer. *Eur J Cancer* 2001;37:1475–1481.
- 27 Brewster SF, Oxley JD, Trivella M, Abbott CD, Gillatt DA: Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. *J Urol* 1999;161:1238–1243.
- 28 Girolodi LA, Bringuier PP, Schalken JA: Defective E-cadherin function in urological cancers: Clinical implications and molecular mechanisms. *Invasion Metastasis* 1994;14:71–81.
- 29 Wu TT, Hsu YS, Wang JS, Lee YH, Huang JK: The role of p53, bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan. *J Urol* 2003;170:78–81.

Announcement

Announcement and Rules C.E. Alken Prize

C.E. Alken Foundation Council

The C.E. Alken Foundation supports clinical and experimental research through an annual prize for outstanding scientific work. The C.E. Alken Prize is awarded for the best unpublished scientific work in the field of urology and may be divided. The prize comprises a certificate and the sum of SFr. 10,000.

Manuscripts can be submitted in either English or German. Seven copies of the manuscript should be sent to the following address and marked for the attention of Mr. E. Hauser, Advocate:

C.E. Alken Foundation, Dr. F. Kellerhals & Partner,
Marktgasse 55, CH–3011 Bern (Switzerland)

The deadline for submission of manuscripts is September 1, 2004. Each paper has to be marked with a code word and must not include the name of the author. An additional sealed envelope (marked on the outside with the code word) has to be enclosed and must contain the following:

- Curriculum vitae of the author (max. 3 pages)
- Structured summary of the manuscript (aim of study, material/methods, results, conclusions)

The award winner will be determined by the Foundation Council, whose decision is final.